Virology News
66.9K views | +0 today
Follow
 
Scooped by Ed Rybicki
onto Virology News
Scoop.it!

Highly Efficient Genome Editing Using Geminivirus-Based CRISPR/Cas9 System in Cotton Plant

Highly Efficient Genome Editing Using Geminivirus-Based CRISPR/Cas9 System in Cotton Plant | Virology News | Scoop.it
Upland cotton (Gossypium hirsutum), an allotetraploid, contains At- and Dt- subgenome and most genes have multiple homologous copies, which pose a huge challenge to investigate genes’ function due to the functional redundancy.
No comment yet.
Virology News
Topical news snippets about viruses that affect people.  And other things. Like Led Zeppelin. And zombies B-)
Curated by Ed Rybicki
Your new post is loading...
Your new post is loading...
Scooped by Ed Rybicki
Scoop.it!

The memory B cell response to influenza vaccination is impaired in older persons

The memory B cell response to influenza vaccination is impaired in older persons | Virology News | Scoop.it
Immune responses to vaccination wane with age. Burton et al. used single-cell RNA
sequencing and flow cytometry of influenza-vaccine-specific B cells to delineate changes
in B cell memory generation, antibody mutation, and their subsequent selection in
older persons.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Moderna says bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant

Moderna says bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant | Virology News | Scoop.it
Moderna released data from a Phase 2-3 clinical trial showing its bivalent COVID-19 booster shot performed better against the BA.4 and BA.5 omicron subvariants.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Study hints at why older people are more susceptible to the flu

Study hints at why older people are more susceptible to the flu | Virology News | Scoop.it
Though the COVID-19 pandemic provided a brief respite, influenza virus is back in circulation and, as usual, poses a special danger to people over the age of 65. But why are older people more susceptible to the flu?
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Why stem cell transplants for MS work so well

Why stem cell transplants for MS work so well | Virology News | Scoop.it
New research digs into why blood stem cell transplants are so effective as a therapy for multiple sclerosis.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Moderna is banking on a combined COVID, flu and RSV vaccine. Will it work?

Moderna is banking on a combined COVID, flu and RSV vaccine. Will it work? | Virology News | Scoop.it
Moderna is developing a combined COVID-19, flu and RSV vaccine — but hasn't released data to show it would work safely.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Influenza A virus reassortment in mammals gives rise to genetically distinct within-host subpopulations

Influenza A virus (IAV) genetic exchange through reassortment has the potential to accelerate viral evolution and has played a critical role in the generation of multiple pandemic strains. For reassortment to occur, distinct viruses must co-infect the same cell.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Chromosome condensation induced by geminivirus infection of mature plant cells

Tomato golden mosaic virus (TGMV) is a geminivirus that replicates its single-stranded DNA genome through double-stranded DNA intermediates in nucl...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

An intranasal COVID vaccine that works against variants in animals

An intranasal COVID vaccine that works against variants in animals | Virology News | Scoop.it
An intranasal vaccine against SARS-CoV-2 could quickly get to the respiratory tract, where the virus most commonly causes symptoms. And a spray or droplets could be a more palatable option for people who fear needles.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Persistence of a 1930 swine influenza A (H1N1) virus in Quebec

Two antigenically distinct H1N1 influenza A viruses were isolated during an outbreak of respiratory disease in Quebec swine in 1990/91. Analysis of...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Researchers design a COVID-19 vaccine construct using hybrid SARS-CoV-2 spike protein and nucleocapsid protein peptides | News-Medical

Researchers design a COVID-19 vaccine construct using hybrid SARS-CoV-2 spike protein and nucleocapsid protein peptides | News-Medical | Virology News | Scoop.it
Researchers designed a COVID-19 vaccine construct using hybrid SARS-CoV-2 S protein (containing SARS-CoV-2 Delta and Omicron variant mutations) and N protein peptides that confer T lymphocyte-mediated immune protection.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants

Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants | Virology News | Scoop.it
SARS-CoV-2 is a rapidly evolving RNA virus that mutates within hosts and exists as
viral quasispecies. Here, we evaluated the within-host diversity among vaccinated
and unvaccinated individuals (n=379) infected with different SARS-CoV-2 variants of
concern.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

The genome organization of banana bunchy top virus: analysis of six ssDNA components

We have cloned, sequenced and analysed an additional five circular ssDNA components of banana bunchy top virus (BBTV) which we have called componen...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Covid vaccine and booster shots in U.S. hit highest weekly level since January

Covid vaccine and booster shots in U.S. hit highest weekly level since January | Virology News | Scoop.it
More than 5.6 million Covid vaccine and booster shots were administered in the past week, the highest seven-day total in the U.S. since January.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Key mutations make monkeypox stronger and smarter

Key mutations make monkeypox stronger and smarter | Virology News | Scoop.it
Like COVID-19, mutations have allowed monkeypox to get smarter, spreading quickly and evading drugs. New research digs into key mutations.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence

The high case-fatality rate--especially among young adults--during the 1918-1919 influenza pandemic is incompletely understood. Although late deaths showed bacterial pneumonia, early deaths exhibited extremely "wet," sometimes hemorrhagic lungs.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Return of seasonal flu, RSV and other viruses could spell disaster for older Canadians, experts say

Return of seasonal flu, RSV and other viruses could spell disaster for older Canadians, experts say | Virology News | Scoop.it
With fewer health care workers to look after the sick, some anticipate this cold and flu season will be especially precarious for older adults...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

The 2022-2023 flu season is on track to be very, very bad

The 2022-2023 flu season is on track to be very, very bad | Virology News | Scoop.it
Don’t wait any longer to get a flu shot...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses

Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses | Virology News | Scoop.it
Current vaccine-induced influenza immunity targets the hypervariable HA head, requiring
frequent vaccine reformulation. Moin et al. show that co-immunization with HA stem immunogens of group 1 and group 2 influenza A viruses broadly elicits cross-protective antibodies in animals and leads to the...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Encapsidated-CpG ODN enhances immunogenicity of porcine circovirus type 2 virus-like particles

A DNA fragment containing CpG motifs (CpG ODN) is one of the potent immunopotentiators used to improve vaccine efficacy. It can enhance a protective immunity by stimulating both innate and adaptive immune responses.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Senegal to Manufacture Affordable Measles, Rubella vaccine 

Senegal to Manufacture Affordable Measles, Rubella vaccine  | Virology News | Scoop.it
HealthHot News Share Institut Pasteur de Dakar (IPD) has launched a new program to advance the development of measles and rubella vaccine for manufacture in Senegal. IPD, a Senegalese private foundation involved in advancing public health and wellbeing in Africa since it was founded in 1896 is one of the four WHO prequalified manufacturers to supply yellow fever vaccine to UN’s Agencies. With support grant from the Bill & Melinda Gates Foundation, IPD shall be producing the vaccine for essential, routine immunization campaigns in low- and middle-income countries and for outbreak and catch-up campaigns. The process will involve the deployment of Batavia’s Hip-Vax intensified production process for GMP measles and rubella material and Univercells’ NevoLine technology platform to accelerate manufacturing and affordable access to essential and epidemic vaccines in Africa. Production will, then be transferred to the state-of-the-art MADIBA facility, a regional manufacturing hub for COVID-19 and other epidemic vaccines with a capacity to produce 300 million doses for use in Africa. According to Dr Amadou Alpha Sall, CEO of IPD, “By manufacturing affordable measles and rubella vaccines and diagnostics in Africa, the region will be one step closer to a diversified manufacturing landscape for epidemic preparedness and improving the supply chain for essential vaccines for routine immunization.” This, he said will help countries in the region build autonomy and reach every child with lifesaving vaccines.” Dr Christopher Yallop, COO of Batavia Biosciences added: “We are privileged to be able to work with Institut Pasteur de Dakar and the Bill & Melinda Gates Foundation to advance this innovative vaccine technology with a key manufacturing partner. Our HIP-Vax manufacturing process technology, developed on the NevoLine™ platform, is designed to deliver vaccines at high yield and very low cost, increasing affordability and availability.” Co-founder of Univercells, José Castillo, said its is is a honour to partner with Institut Pasteur de Dakar and Batavia Biosciences in this historic initiative, which they hope will increase access to the measles and rubella vaccines in Africa. “We are thrilled that our technology will help enable progress towards regional autonomy. Knowing that our breakthrough vaccine manufacturing platform NevoLine™, initially funded by the Bill & Melinda Gates Foundation in 2016, will now help accelerate the manufacture of vaccines in Africa, is very exciting,” Castillo said.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Tweak could lead to COVID vax that fights new variants

Tweak could lead to COVID vax that fights new variants | Virology News | Scoop.it
The new design "could be used not just for SARS-CoV-2 and other related viruses, but also for other clinically important pathogenic viruses."...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Complementation of African cassava mosaic virus AC2 gene function in a mixed bipartite geminivirus infection

We have previously demonstrated that African cassava mosaic virus (ACMV) DNAs A and B efficiently complement the systemic spread of tomato golden m...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Mutational analysis of potato yellow mosaic geminivirus

Mutations have been inserted into the virion and complementary sense ORFs encoding proteins with M(r)s in excess of 9 kDa of both DNA A and DNA B o...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Biden receives updated COVID booster shot, urges Americans to do the same

Biden receives updated COVID booster shot, urges Americans to do the same | Virology News | Scoop.it
The president touted new efforts by companies to get the shots in more arms ahead of an expected surge in new infections.
No comment yet.